Back to search
Prurigo Nodularis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Prurigo Nodularis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Prurigo Nodularis trials you may qualify forThe purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
This study is the first-in-human (FIH) study of BGB-45035. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGB-45035…
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outco…
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment…
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure…
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Around one-third of patients with AD have had at l…